$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2014 Q4 Form 10-Q Financial Statement

#000114420414069728 Filed on November 19, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q2
Revenue $872.0K $582.0K $0.00
YoY Change 45.5% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.240M $4.140M $3.880M
YoY Change 47.61% 35.29% 17.93%
% of Gross Profit
Research & Development $21.40M $22.71M $21.55M
YoY Change 92.45% 77.48% 157.06%
% of Gross Profit
Depreciation & Amortization -$340.0K $346.0K $10.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $26.64M $22.71M $21.55M
YoY Change 81.6% 77.48% 157.06%
Operating Profit -$26.61M -$25.43M
YoY Change 72.15% 122.97%
Interest Expense -$17.31M $271.0K $33.00K
YoY Change -1961.29% 310.61% -82.63%
% of Operating Profit
Other Income/Expense, Net -$17.26M $5.565M -$438.0K
YoY Change 447.9% -174.7%
Pretax Income -$42.69M -$21.04M -$25.87M
YoY Change 152.75% -8.16% 123.21%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$42.69M -$21.04M -$25.87M
YoY Change 152.72% -8.15% 123.09%
Net Earnings / Revenue -4895.07% -3615.64%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$642.1K -$0.35 -$450.4K
COMMON SHARES
Basic Shares Outstanding 62.22M shares 60.60M shares 57.20M shares
Diluted Shares Outstanding 60.60M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.39M $1.400M $8.850M
YoY Change -27.62% -51.05% 344.72%
Cash & Equivalents $13.39M $1.403M $8.853M
Short-Term Investments
Other Short-Term Assets $1.260M $170.0K $3.590M
YoY Change 740.0% -96.34% 897.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.64M $1.570M $12.44M
YoY Change -21.47% -79.07% 429.98%
LONG-TERM ASSETS
Property, Plant & Equipment $40.00M $23.91M $77.00K
YoY Change 48091.57% 16981.43% -13.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $55.00K $55.00K $55.00K
YoY Change 0.0%
Total Long-Term Assets $41.81M $27.82M $132.0K
YoY Change 30200.0% 20510.37% 48.31%
TOTAL ASSETS
Total Short-Term Assets $14.64M $1.570M $12.44M
Total Long-Term Assets $41.81M $27.82M $132.0K
Total Assets $56.46M $29.39M $12.58M
YoY Change 200.55% 284.94% 416.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.826M $11.50M $9.543M
YoY Change 9.95% 5.16% -37.66%
Accrued Expenses $1.211M $790.0K $655.0K
YoY Change 43.82% -32.48% -39.8%
Deferred Revenue
YoY Change
Short-Term Debt $930.0K $930.0K $930.0K
YoY Change 0.0% 0.0% 0.0%
Long-Term Debt Due $6.370M $240.0K $240.0K
YoY Change 2096.55% -64.18% -82.09%
Total Short-Term Liabilities $75.01M $43.30M $42.45M
YoY Change 280.96% 151.45% 127.31%
LONG-TERM LIABILITIES
Long-Term Debt $16.38M $15.72M $0.00
YoY Change
Other Long-Term Liabilities $98.00K $1.600M
YoY Change -66.1%
Total Long-Term Liabilities $16.48M $17.32M $0.00
YoY Change 266.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $75.01M $43.30M $42.45M
Total Long-Term Liabilities $16.48M $17.32M $0.00
Total Liabilities $91.48M $60.61M $42.45M
YoY Change 364.64% 176.25% 127.32%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $485.7M $446.8M $427.2M
YoY Change 29.43% 30.23% 34.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$35.03M -$31.22M -$29.87M
YoY Change
Total Liabilities & Shareholders Equity $56.46M $29.39M $12.58M
YoY Change 200.55% 284.99% 416.04%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income -$42.69M -$21.04M -$25.87M
YoY Change 152.72% -8.15% 123.09%
Depreciation, Depletion And Amortization -$340.0K $346.0K $10.00K
YoY Change 0.0%
Cash From Operating Activities -$18.60M -$8.480M -$16.94M
YoY Change 27.4% 7.07% 106.33%
INVESTING ACTIVITIES
Capital Expenditures -$11.40M -$22.33M
YoY Change -22900.0% 44560.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $780.0K -$3.410M
YoY Change -100.0% -117.33%
Cash From Investing Activities -$11.39M -$21.55M -$3.410M
YoY Change -350.33% 373.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.98M 22.57M 16.98M
YoY Change 63.41% 69.19% 72.91%
NET CHANGE
Cash From Operating Activities -18.60M -8.480M -16.94M
Cash From Investing Activities -11.39M -21.55M -3.410M
Cash From Financing Activities 41.98M 22.57M 16.98M
Net Change In Cash 11.99M -7.460M -3.370M
YoY Change -23.34% -957.47% -309.32%
FREE CASH FLOW
Cash From Operating Activities -$18.60M -$8.480M -$16.94M
Capital Expenditures -$11.40M -$22.33M
Free Cash Flow -$7.200M $13.85M
YoY Change -50.85% -275.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
46000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
375213000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-9818000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18784000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
1570000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55000 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
167000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23914000 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
62000 USD
CY2014Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
8913000 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1403000 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
446744000 USD
CY2014Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
477836000 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
384887000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-190000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-190000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-31220000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29394000 USD
nwbo Lock Up Agreement Description
LockUpAgreementDescription
The Company also entered into a Lock-Up Agreement with Cognate on January 17, 2014, under which Cognate agreed to have all of the shares that are issued as part of the milestone and initiation payments and the invoice conversions under the Cognate Agreements (collectively, the Lock-Up Shares) locked up for up to 36 months, in return for 15% warrant coverage for each 6-month period of lock-up, on the same terms as the warrants in the Cognate Agreements. During the lock-up, the Lock-Up Shares may not be sold or traded on the market. These lock-up terms are subject to the same most favored nation treatment as provided in the Cognate Agreements as described above.
nwbo Share Based Compensation Aggregate Non Cash Charges For Non Cash Interest Associated With Accretion Of Our Convertible Notes Discount Net
ShareBasedCompensationAggregateNonCashChargesForNonCashInterestAssociatedWithAccretionOfOurConvertibleNotesDiscountNet
37800000 USD
CY2014Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1600000 USD
CY2014Q3 nwbo Current Assets Less Payables
CurrentAssetsLessPayables
11900000 USD
CY2014Q3 nwbo Convertible Notes Payable Related Parties
ConvertibleNotesPayableRelatedParties
2400000 USD
CY2014Q3 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
2343000 USD
CY2013Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
3619000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
900000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
100000 USD
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
400000 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
70000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19232000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32992000 shares
CY2013 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
3600000 USD
nwbo One Time Charges Of Service Agreement
OneTimeChargesOfServiceAgreement
12700000 USD
CY2013Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
8900000 USD
CY2014Q3 nwbo Accrued Expenses Related Party
AccruedExpensesRelatedParty
8000 USD
CY2013Q4 nwbo Accrued Expenses Related Party
AccruedExpensesRelatedParty
5000 USD
CY2014Q3 nwbo Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
50000 USD
CY2013Q4 nwbo Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
50000 USD
CY2014Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
1444788 shares
CY2014Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1444788 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62218685 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45666315 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62218685 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45666315 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000000 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
900000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5101366 shares
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2000000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
CY2014Q3 nwbo Convertible Notes Payable Current Related Parties
ConvertibleNotesPayableCurrentRelatedParties
50000 USD
CY2013Q4 nwbo Convertible Notes Payable Current Related Parties
ConvertibleNotesPayableCurrentRelatedParties
75000 USD
CY2014Q3 us-gaap Notes Payable
NotesPayable
16889000 USD
CY2013Q4 us-gaap Notes Payable
NotesPayable
1222000 USD
CY2013Q1 nwbo Potential Redeemable Shares Eligible
PotentialRedeemableSharesEligible
1400000 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20116000 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25581000 shares
CY2014Q2 nwbo Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable
ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable
364000 shares
CY2014Q3 nwbo Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable
ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable
1121000 shares
CY2014Q1 nwbo Number Of Warrants Warrants Issued In Exchange For Services
NumberOfWarrantsWarrantsIssuedInExchangeForServices
2434000 shares
CY2014Q3 nwbo Number Of Warrants Warrants Issued In Exchange For Services
NumberOfWarrantsWarrantsIssuedInExchangeForServices
17000 shares
CY2014Q1 nwbo Class Of Warrant Or Right Issued To Connection With Common Stock Issued
ClassOfWarrantOrRightIssuedToConnectionWithCommonStockIssued
150000 shares
CY2014Q2 nwbo Class Of Warrant Or Right Issued To Connection With Common Stock Issued
ClassOfWarrantOrRightIssuedToConnectionWithCommonStockIssued
281000 shares
CY2014Q1 nwbo Number Of Warrants Warrants Exercised On Cashless Basis
NumberOfWarrantsWarrantsExercisedOnCashlessBasis
73000 shares
CY2014Q1 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
722000 shares
CY2014Q2 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
90000 shares
CY2014Q3 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
497000 shares
CY2014Q2 nwbo Class Of Warrant Or Right Issued In Connection With Registered Direct Offering
ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOffering
2273000 shares
CY2014Q2 nwbo Class Of Warrant Or Right Issued To Placement Agent In Connection With Registered Direct Offering
ClassOfWarrantOrRightIssuedToPlacementAgentInConnectionWithRegisteredDirectOffering
113000 shares
CY2014Q1 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
6000 shares
CY2014Q3 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
1000 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
28962000 shares
CY2013Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.23
CY2014Q1 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.32
CY2014Q1 nwbo Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice
4.00
CY2014Q2 nwbo Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice
4.00
CY2014Q3 nwbo Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice
4.00
CY2014Q1 nwbo Class Of Warrant Or Right Issued In Exchange Of Services Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInExchangeOfServicesWeightedAverageExercisePrice
4.00
CY2014Q3 nwbo Class Of Warrant Or Right Issued In Exchange Of Services Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInExchangeOfServicesWeightedAverageExercisePrice
6.33
CY2014Q1 nwbo Class Of Warrant Or Right Issued To Connection With Common Stock Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedToConnectionWithCommonStockWeightedAverageExercisePrice
5.00
CY2014Q2 nwbo Class Of Warrant Or Right Issued To Connection With Common Stock Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedToConnectionWithCommonStockWeightedAverageExercisePrice
4.00
CY2014Q1 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
3.66
CY2014Q2 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
4.25
CY2014Q3 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
3.48
CY2014Q1 nwbo Weighted Average Exercise Pricewarrants Exercised On Cashless Basis
WeightedAverageExercisePricewarrantsExercisedOnCashlessBasis
0
CY2014Q2 nwbo Class Of Warrant Or Right Issued In Connection With Registered Direct Offering Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOfferingWeightedAverageExercisePrice
7.50
CY2014Q2 nwbo Class Of Warrant Or Right Issued To Placement Agent In Connection With Registered Direct Offering In Exchange Of Services Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedToPlacementAgentInConnectionWithRegisteredDirectOfferingInExchangeOfServicesWeightedAverageExercisePrice
8.25
CY2014Q1 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
9.54
CY2014Q3 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
7.63
CY2014Q3 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
4.90
us-gaap Revenue From Grants
RevenueFromGrants
809000 USD
us-gaap Revenue From Grants
RevenueFromGrants
582000 USD
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
400000 USD
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
582000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
809000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
582000 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
400000 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
582000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32785000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64242000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12794000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22707000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8819000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11707000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3059000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4137000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
352000 USD
CY2013Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000 USD
CY2014Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
346000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
41613000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
76301000 USD
CY2013Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15856000 USD
CY2014Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
27190000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-40804000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-75719000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15456000 USD
CY2014Q2 nwbo Stock Issued During Period Value Conversion Of Accounts Payable To Common Stock And Warrants
StockIssuedDuringPeriodValueConversionOfAccountsPayableToCommonStockAndWarrants
2909000 USD
CY2014Q3 nwbo Stock Issued During Period Value Conversion Of Accounts Payable To Common Stock And Warrants
StockIssuedDuringPeriodValueConversionOfAccountsPayableToCommonStockAndWarrants
7945000 USD
CY2014Q1 nwbo Adjustment To Additional Paid In Capital Inducement Expenses Associated With Conversion Convertible Debt
AdjustmentToAdditionalPaidInCapitalInducementExpensesAssociatedWithConversionConvertibleDebt
2800000 USD
CY2014Q2 nwbo Adjustment To Additional Paid In Capital Inducement Expenses Associated With Conversion Convertible Debt
AdjustmentToAdditionalPaidInCapitalInducementExpensesAssociatedWithConversionConvertibleDebt
1525000 USD
CY2014Q1 nwbo Stock Issued During Period Value Conversion Of Note Payable And Accrued Interest
StockIssuedDuringPeriodValueConversionOfNotePayableAndAccruedInterest
217000 USD
CY2014Q1 nwbo Stock Issued During Period Value Proceeds From Warrants Exercises
StockIssuedDuringPeriodValueProceedsFromWarrantsExercises
2692000 USD
CY2014Q2 nwbo Stock Issued During Period Value Proceeds From Warrants Exercises
StockIssuedDuringPeriodValueProceedsFromWarrantsExercises
395000 USD
CY2014Q3 nwbo Stock Issued During Period Value Proceeds From Warrants Exercises
StockIssuedDuringPeriodValueProceedsFromWarrantsExercises
1730000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26608000 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
7451000 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
18506000 USD
CY2013Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
7451000 USD
CY2014Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
8166000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
63000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1702000 USD
CY2013Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
63000 USD
CY2014Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
14002000 USD
us-gaap Interest Expense
InterestExpense
706000 USD
us-gaap Interest Expense
InterestExpense
426000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
66000 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
271000 USD
us-gaap Net Income Loss
NetIncomeLoss
-48898000 USD
us-gaap Net Income Loss
NetIncomeLoss
-92949000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-22910000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-21043000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.60
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30605000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56838000 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35275000 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60604000 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
238496 shares
CY2014Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
24924 shares
CY2014Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
14519 shares
CY2014Q1 nwbo Fair Value Of Common Stock For Convertible Accounts
FairValueOfCommonStockForConvertibleAccounts
2500000 USD
CY2014Q1 nwbo Inducement Expenses
InducementExpenses
5300000 USD
CY2014Q1 nwbo Redeemable Shares Number
RedeemableSharesNumber
1444788 shares
CY2014Q1 nwbo Stock Issued During Period Shares Exercise Of Warrant
StockIssuedDuringPeriodSharesExerciseOfWarrant
721827 shares
CY2014Q1 nwbo Stock Issued During Period Value Exercise Of Warrant
StockIssuedDuringPeriodValueExerciseOfWarrant
2700000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1600000 USD
CY2014Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
155607 USD
CY2014Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
94999 USD
CY2014Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
2272727 shares
CY2014Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
15000000 USD
CY2014Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
4500000 USD
CY2014Q3 nwbo Fair Value Of Warrants At Issuance Date
FairValueOfWarrantsAtIssuanceDate
3800000 USD
CY2014Q2 nwbo Reclassification Of Equity Instruments Shares
ReclassificationOfEquityInstrumentsShares
200000 shares
CY2014Q3 nwbo Reclassification Of Equity Instruments Shares
ReclassificationOfEquityInstrumentsShares
3013 shares
CY2014Q3 nwbo Reclassification Of Equity Instruments Shares
ReclassificationOfEquityInstrumentsShares
49107 shares
CY2014Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.60
CY2014Q1 nwbo Proceeds From Shares Payable
ProceedsFromSharesPayable
1400000 USD
CY2014Q2 nwbo Proceeds From Shares Payable
ProceedsFromSharesPayable
1400000 USD
CY2014Q3 nwbo Proceeds From Shares Payable
ProceedsFromSharesPayable
15000 USD
CY2014Q3 nwbo Proceeds From Shares Payable
ProceedsFromSharesPayable
275000 USD
CY2014Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
92100 shares
CY2014Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
497133 shares
CY2014Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
395000 USD
CY2014Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
7900000 USD
CY2014Q4 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2014Q1 nwbo Stock Issued During Period Value Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValuePrivatePlacementNetOfOfferingCosts
224000 USD
CY2014Q1 nwbo Stock Issued During Period Value Conversion Of Accounts Payable To Common Stock And Warrants
StockIssuedDuringPeriodValueConversionOfAccountsPayableToCommonStockAndWarrants
5927000 USD
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23199000 USD
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
15507000 USD
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
-17000 USD
CY2014Q1 nwbo Cashless Exercises Of Warrants Value
CashlessExercisesOfWarrantsValue
0 USD
CY2014Q2 nwbo Cashless Exercises Of Warrants Value
CashlessExercisesOfWarrantsValue
0 USD
CY2014Q1 nwbo Stock Issued During Period Value Redemption Of Redeemable Securities
StockIssuedDuringPeriodValueRedemptionOfRedeemableSecurities
8913000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2014Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2000 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1000 USD
CY2014Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1104000 USD
CY2014Q2 nwbo Stock Issued During Period Value Issued For Exchange For Services Non Employees
StockIssuedDuringPeriodValueIssuedForExchangeForServicesNonEmployees
155000 USD
CY2014Q3 nwbo Stock Issued During Period Value Issued For Exchange For Services Non Employees
StockIssuedDuringPeriodValueIssuedForExchangeForServicesNonEmployees
95000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2460000 USD
CY2014Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2662000 USD
CY2014Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
871000 USD
CY2014Q1 nwbo Stock Issued During Period Value Issued For Services Non Employees
StockIssuedDuringPeriodValueIssuedForServicesNonEmployees
1567000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-31060000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
-29872000 USD
CY2014Q2 nwbo Issuance Of Common Stock Value For Cash And Overallotment Rights
IssuanceOfCommonStockValueForCashAndOverallotmentRights
15000000 USD
CY2014Q2 nwbo Stock And Warrants Value Issued Under Private Placement
StockAndWarrantsValueIssuedUnderPrivatePlacement
1835000 USD
CY2014Q2 nwbo Stock And Warrants Value Issued
StockAndWarrantsValueIssued
2250000 USD
CY2014Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1426000 USD
CY2014Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
4427000 USD
CY2014Q2 nwbo Subscription Receivable For Issuance Of Common Stock Value
SubscriptionReceivableForIssuanceOfCommonStockValue
0 USD
CY2014Q3 nwbo Subscription Receivable For Issuance Of Common Stock Value
SubscriptionReceivableForIssuanceOfCommonStockValue
125000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-46041000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-25865000 USD
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
9000 USD
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
352000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
497000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
71000 USD
nwbo Accrued Interest Converted To Preferred Stock
AccruedInterestConvertedToPreferredStock
0 USD
nwbo Accrued Interest Converted To Preferred Stock
AccruedInterestConvertedToPreferredStock
76000 USD
nwbo Accreted Interest On Convertible Promissory Note
AccretedInterestOnConvertiblePromissoryNote
61000 USD
nwbo Accreted Interest On Convertible Promissory Note
AccretedInterestOnConvertiblePromissoryNote
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1350000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
nwbo Nonemployee Share Based Compensation
NonemployeeShareBasedCompensation
0 USD
nwbo Nonemployee Share Based Compensation
NonemployeeShareBasedCompensation
18656000 USD
nwbo Stock And Warrants Issued For Services And Other Expenses
StockAndWarrantsIssuedForServicesAndOtherExpenses
1625000 USD
nwbo Stock And Warrants Issued For Services And Other Expenses
StockAndWarrantsIssuedForServicesAndOtherExpenses
1819000 USD
nwbo Inducement Expenses
InducementExpenses
7319000 USD
nwbo Inducement Expenses
InducementExpenses
18506000 USD
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
26000 USD
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
20000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1119000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3654000 USD
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
13791000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35980000 USD
nwbo Increase Decrease In Cash In Custody Account
IncreaseDecreaseInCashInCustodyAccount
-4500000 USD
nwbo Increase Decrease In Cash In Custody Account
IncreaseDecreaseInCashInCustodyAccount
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4554000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24957000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
688000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4817000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2250000 USD
nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
24001000 USD
nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
6684000 USD
nwbo Proceeds From Issuance Of Common Stock Over Allotment Rights
ProceedsFromIssuanceOfCommonStockOverAllotmentRights
0 USD
nwbo Proceeds From Issuance Of Common Stock Over Allotment Rights
ProceedsFromIssuanceOfCommonStockOverAllotmentRights
15000000 USD
nwbo Repayments Of Offering Costs
RepaymentsOfOfferingCosts
0 USD
nwbo Repayments Of Offering Costs
RepaymentsOfOfferingCosts
1105000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23264000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43841000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4489000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17096000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7346000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2857000 USD
nwbo Reclass Of Redeemable Security To Equity
ReclassOfRedeemableSecurityToEquity
1307000 USD
nwbo Reclass Of Redeemable Security To Equity
ReclassOfRedeemableSecurityToEquity
8913000 USD
CY2014Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
17500000 USD
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Embedded Derivatives</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company has issued financial instruments such as debt in which a derivative instrument is &#8220;embedded.&#8221; Upon issuing the financial instrument, the Company assesses whether the economic characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate, non-embedded instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract and (2) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is separated from the host contract and carried at fair value, with changes in fair value recorded in the consolidated statements of operations. The <font style="BACKGROUND-COLOR: transparent"> convertible notes contain an interest make-whole payment provision pursuant to which holders who convert their notes prior to maturity will receive, all interest due through the term of the note. Under ASC 815-10-15-74(a), the interest make-whole payment is considered an embedded derivative and is separated from the host contract,&#160;</font> <font style="BACKGROUND-COLOR: transparent"> the convertible notes are&#160;carried at fair value. As of September 30, 2014, the carrying amount of embedded derivatives</font> <font style="BACKGROUND-COLOR: transparent"> associated with</font> <font style="BACKGROUND-COLOR: transparent"> the convertible&#160;</font> <font style="BACKGROUND-COLOR: transparent">notes was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1200000 USD
CY2014Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
27824000 USD
CY2013Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
138000 USD
CY2014Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
17317000 USD
CY2013Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 USD
CY2014Q3 us-gaap Liabilities
Liabilities
60614000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
19689000 USD
CY2014Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
15717000 USD
CY2014Q3 us-gaap Escrow Deposit
EscrowDeposit
2625000 USD
CY2013Q4 us-gaap Escrow Deposit
EscrowDeposit
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24414000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
231000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
500000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
148000 USD
us-gaap Depreciation
Depreciation
400000 USD
CY2013Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001072379
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
NWBO
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62218685 shares
CY2014Q3 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
29831000 USD
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
8688000 USD
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
33624000 USD
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
31078000 USD
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
29831000 USD
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
7952000 USD
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
2138000 USD
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
12755000 USD
CY2014Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
16984000 USD
CY2014Q2 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-4684000 USD
CY2014Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-14002000 USD
CY2014Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1230000 USD
CY2013Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
50000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22332000 USD
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
1005000 USD
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
209000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
25000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
605000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Payments For Repurchase Of Redeemable Preferred Stock
PaymentsForRepurchaseOfRedeemablePreferredStock
240000 USD
us-gaap Payments For Repurchase Of Redeemable Preferred Stock
PaymentsForRepurchaseOfRedeemablePreferredStock
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
16220000 USD
CY2014Q3 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
4500000 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
0 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
2625000 USD
CY2014Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
17500000 USD
CY2014Q3 us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.05 pure
CY2014Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
7.30
CY2014Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16200000 USD
nwbo Percentage Of Initial Purchase Price
PercentageOfInitialPurchasePrice
0.3 pure
CY2014Q3 nwbo Warrants Issued During Period
WarrantsIssuedDuringPeriod
2325467 shares
CY2014Q3 nwbo Warrants Expiration Period
WarrantsExpirationPeriod
P5Y
CY2014Q3 nwbo Warrants Initial Exercise Price
WarrantsInitialExercisePrice
4.00
invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
2.38
CY2014Q3 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
3.08
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
1280000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
251000 USD
CY2014Q3 nwbo Reclassification Of Additional Paid In Capital Excess Amount To Interest Expense
ReclassificationOfAdditionalPaidInCapitalExcessAmountToInterestExpense
1873 USD
CY2014Q3 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
50000 USD
CY2014Q1 nwbo Value Of Notes Converted To Common Stock
ValueOfNotesConvertedToCommonStock
200000 USD
CY2014Q1 nwbo Number Of Common Shares From Notes Conversion
NumberOfCommonSharesFromNotesConversion
70000 shares
CY2014Q1 nwbo Reclassification Of Redeemable Shares To Equity Value
ReclassificationOfRedeemableSharesToEquityValue
8900000 USD
CY2014Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
125550 USD
CY2014Q3 us-gaap Accrued Environmental Loss Contingencies Noncurrent
AccruedEnvironmentalLossContingenciesNoncurrent
1600000 USD
CY2013Q4 us-gaap Accrued Environmental Loss Contingencies Noncurrent
AccruedEnvironmentalLossContingenciesNoncurrent
0 USD
us-gaap Environmental Expense And Liabilities
EnvironmentalExpenseAndLiabilities
0 USD
us-gaap Environmental Expense And Liabilities
EnvironmentalExpenseAndLiabilities
1600000 USD
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 USD
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
1854000 USD
nwbo Cash Payments
CashPayments
7400000 USD
nwbo Cash Payments
CashPayments
12800000 USD
CY2013Q3 nwbo Cash Payments
CashPayments
1400000 USD
CY2014Q3 nwbo Cash Payments
CashPayments
1400000 USD
nwbo Cash Payments For Services
CashPaymentsForServices
19200000 USD
nwbo Cash Payments For Services
CashPaymentsForServices
2300000 USD
CY2013Q3 nwbo Cash Payments For Services
CashPaymentsForServices
8600000 USD
CY2014Q3 nwbo Cash Payments For Services
CashPaymentsForServices
2300000 USD
CY2014Q3 nwbo Cash And Noncash Expenses For Service
CashAndNoncashExpensesForService
16900000 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
32600000 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
45400000 USD
CY2013Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
12750000 USD
CY2014Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
14700000 USD
us-gaap Site Contingency Loss Exposure In Excess Of Accrual High Estimate
SiteContingencyLossExposureInExcessOfAccrualHighEstimate
1000000 USD
us-gaap Site Contingency Loss Exposure In Excess Of Accrual Low Estimate
SiteContingencyLossExposureInExcessOfAccrualLowEstimate
20000000 USD
us-gaap Site Contingency Loss Exposure In Excess Of Accrual Best Estimate
SiteContingencyLossExposureInExcessOfAccrualBestEstimate
1600000 USD
us-gaap Debt Instrument Issuer
DebtInstrumentIssuer
Northwest Biotherapeutics, Inc. (the &#8220;Company&#8221;)
us-gaap Debt Instrument Maturity Date Range Start1
DebtInstrumentMaturityDateRangeStart1
2014-08-14
CY2014Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
1783000 USD
CY2014Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
1783000 USD
CY2013Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
0 USD
CY2014Q2 nwbo Proceed From Exercise Of Warrants
ProceedFromExerciseOfWarrants
394925 USD
nwbo Warrants Issued During Period
WarrantsIssuedDuringPeriod
9622907 shares
nwbo Warrants Issued Weighted Average Exercise Price Per Warrant
WarrantsIssuedWeightedAverageExercisePricePerWarrant
3.00
nwbo Warrants Issuedweighted Average Remaining Contractual Term
WarrantsIssuedweightedAverageRemainingContractualTerm
P3Y9M18D
CY2014Q3 nwbo Number Of Warrants Warrants Issued To Cognate For Services
NumberOfWarrantsWarrantsIssuedToCognateForServices
2326000 shares
CY2014Q3 nwbo Class Of Warrant Or Right Issued To Cognate For Services Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedToCognateForServicesWeightedAverageExercisePrice
4.00

Files In Submission

Name View Source Status
0001144204-14-069728-index-headers.html Edgar Link pending
0001144204-14-069728-index.html Edgar Link pending
0001144204-14-069728.txt Edgar Link pending
0001144204-14-069728-xbrl.zip Edgar Link pending
ex10-1x10x1.jpg Edgar Link pending
ex10-1x11x1.jpg Edgar Link pending
ex10-1x12x1.jpg Edgar Link pending
ex10-1x13x1.jpg Edgar Link pending
ex10-1x14x1.jpg Edgar Link pending
ex10-1x15x1.jpg Edgar Link pending
ex10-1x16x1.jpg Edgar Link pending
ex10-1x17x1.jpg Edgar Link pending
ex10-1x18x1.jpg Edgar Link pending
ex10-1x19x1.jpg Edgar Link pending
ex10-1x1x1.jpg Edgar Link pending
ex10-1x20x1.jpg Edgar Link pending
ex10-1x21x1.jpg Edgar Link pending
ex10-1x22x1.jpg Edgar Link pending
ex10-1x23x1.jpg Edgar Link pending
ex10-1x24x1.jpg Edgar Link pending
ex10-1x25x1.jpg Edgar Link pending
ex10-1x26x1.jpg Edgar Link pending
ex10-1x27x1.jpg Edgar Link pending
ex10-1x28x1.jpg Edgar Link pending
ex10-1x29x1.jpg Edgar Link pending
ex10-1x2x1.jpg Edgar Link pending
ex10-1x3x1.jpg Edgar Link pending
ex10-1x4x1.jpg Edgar Link pending
ex10-1x5x1.jpg Edgar Link pending
ex10-1x6x1.jpg Edgar Link pending
ex10-1x7x1.jpg Edgar Link pending
ex10-1x8x1.jpg Edgar Link pending
ex10-1x9x1.jpg Edgar Link pending
ex10-2x1.jpg Edgar Link pending
ex10-2x2.jpg Edgar Link pending
ex10-2x3.jpg Edgar Link pending
ex10-2x4.jpg Edgar Link pending
ex10-2x5.jpg Edgar Link pending
ex10-2x6.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nwbo-20140930.xml Edgar Link completed
nwbo-20140930.xsd Edgar Link pending
nwbo-20140930_cal.xml Edgar Link unprocessable
nwbo-20140930_def.xml Edgar Link unprocessable
nwbo-20140930_lab.xml Edgar Link unprocessable
nwbo-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v393316_10q.htm Edgar Link pending
v393316_ex10-1.htm Edgar Link pending
v393316_ex10-2.htm Edgar Link pending
v393316_ex31-1.htm Edgar Link pending
v393316_ex32-1.htm Edgar Link pending